U.S. markets closed
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow 30

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Russell 2000

    2,335.81
    +24.40 (+1.06%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Silver

    28.05
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2107
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • USD/JPY

    109.6350
    +0.2870 (+0.26%)
     
  • BTC-USD

    35,869.44
    -198.53 (-0.55%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    28,948.73
    -9.83 (-0.03%)
     

Should You Buy Cassava Sciences Stock Now?

·4 min read
Should You Buy Cassava Sciences Stock Now?
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Alzheimer's disease drug developer Cassava Sciences (NASDAQ: SAVA) have soared this year thanks to progress with a potential new drug called sumifilam. Does simufilam have a clear enough shot at success to make Cassava Sciences a smart investment right now? Cassava Sciencesa's lead candidate, sumifilam is a potential new dementia treatment that restores the shape and function of an important structural protein found in the brain called filamin A. Last November, Cassava sciences reported clinical trial results for sumifilam that suggest stabilizing this protein has an important knock-on effect.